CRP and endothelial dysfunction: Selected biomarkers were chosen based on prior evidence linking them to platelet activation (sCD40-L), systemic inflammation (hs-CRP), and endothelial dysfunction (VCAM-1) – all of which are implicated in CMVO pathogenesis.